

Chemotherapy Induced Peripheral Neuropathy Treatment Market 20262031

<https://marketpublishers.com/r/CF3A3ED35005EN.html>

Date: November 2025

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: CF3A3ED35005EN

Abstracts

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at in and is anticipated to reach by 2031, at a CAGR of 0.05 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Chemotherapy Induced Peripheral Neuropathy Treatment Market.

This report delivers a comprehensive overview of the Chemotherapy Induced Peripheral Neuropathy Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment Market. The Chemotherapy Induced Peripheral Neuropathy Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –2031.

Chemotherapy Induced Peripheral Neuropathy Treatment Market Scope:

Key Players

Asahi Kasei Pharma Corp

Regency Pharmaceuticals

MAKScientific LLC

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Immune Pharmaceuticals Inc.

Solasia Pharma K.K.

Major Highlights

This report delivers a comprehensive overview of the Chemotherapy Induced Peripheral Neuropathy Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment Market. The Chemotherapy Induced Peripheral Neuropathy Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Product
- 3.2. Market Snippet by Application
- 3.3. Market Snippet by End-Users
- 3.4. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
- 4.2. Drivers
 - 4.2.1. Increasing incidence of cancer
 - 4.2.2. Rising awareness in emerging economies
- 4.3. Restraints:
 - 4.3.1. Side-effects of treatment
- 4.4. Opportunity
- 4.5. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Value Chain Analysis
- 5.4. PEST Analysis
- 5.5. Pricing Analysis
- 5.6. Regulatory Analysis
- 5.7. Reimbursement Analysis
- 5.8. Unmet Needs
- 5.9. Patent Trends

6. COVID-19 ANALYSIS

6.1. Analysis of Covid-19 on the Market

- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario

6.2. Pricing Dynamics Amid Covid-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During Pandemic

6.5. Manufacturers Strategic Initiatives

6.6. Conclusion

7. BY PRODUCT

7.1. Introduction

7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment

7.3. Market Attractiveness Index, By Product Segment

7.3.1. Calcium Channel β -delta Ligands*

7.3.1.1. Introduction

7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

7.3.2. Antidepressants

7.3.3. Opioids

7.3.4. Others

8. BY APPLICATION

8.1. Introduction

8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment

8.3. Market Attractiveness Index, By Application Segment

8.3.1. Platinum Agents*

8.3.1.1. Introduction

8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

8.3.2. Taxanes

8.3.3. Vinca Alkaloids

8.3.4. Others

9. BY END-USERS

9.1. Introduction

9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment

9.3. Market Attractiveness Index, By End-Users Segment

9.3.1. Hospitals & Clinics*

9.3.1.1. Introduction

9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

9.3.2. Cancer Centers

10. BY REGION

10.1. Introduction

10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

10.3. Market Attractiveness Index, By Region

10.4. North America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.4.6.1. The U.S.

10.4.6.2. Canada

10.4.6.3. Mexico

10.5. Europe

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.5.6.1. Germany

10.5.6.2. The U.K.

10.5.6.3. France

10.5.6.4. Italy

10.5.6.5. Spain

10.5.6.6. Rest of Europe

10.6. South America

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.6.6.1. Brazil

10.6.6.2. Argentina

10.6.6.3. Rest of South America

10.7. Asia Pacific

10.7.1. Introduction

10.7.2. Key Region-Specific Dynamics

10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10.7.6.1. China

10.7.6.2. India

10.7.6.3. Japan

10.7.6.4. Australia

10.7.6.5. Rest of Asia Pacific

10.8. The Middle East and Africa

10.8.1. Introduction

10.8.2. Key Region-Specific Dynamics

10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product

10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. Asahi Kasei Pharma Corp*

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Key Highlights

12.1.4. Financial Overview

- 12.2. Regency Pharmaceuticals
- 12.3. MAKScientific LLC
- 12.4. Metys Pharmaceuticals AG
- 12.5. Nemus Bioscience Inc
- 12.6. PledPharma
- 12.7. Sova Pharmaceuticals Inc
- 12.8. DermaXon LLC
- 12.9. Immune Pharmaceuticals Inc.
- 12.10. Solasia Pharma K.K.

13. DATAM INTELLIGENCE

- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us

I would like to order

Product name: Chemotherapy Induced Peripheral Neuropathy Treatment Market 20262031

Product link: <https://marketpublishers.com/r/CF3A3ED35005EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CF3A3ED35005EN.html>